RT Journal Article
T1 OMIC technologies and vaccine development: from the identification of vulnerable individuals to the formulation of invulnerable vaccines
A1 Cotugno, Nicola
A1 Ruggiero, Alessandra
A1 Santilli, Veronica
A1 Manno, Emma Concetta
A1 Rocca, Salvatore
A1 Zicari, Sonia
A1 Amodio, Donato
A1 Colucci, Manuela
A1 Rossi, Paolo
A1 Levy, Ofer
A1 Martinón Torres, Federico
A1 Pollard, Andrew J.
A1 Palma, Paolo
AB Routine vaccination is among the most effective clinical interventions to prevent diseases as it is estimated to save over 3 million lives every year. However, the full potential of global immunization programs is not realised because population coverage is still suboptimal. This is also due to the inadequate immune response and paucity of informative correlates of protection upon immunization of vulnerable individuals such as newborns, preterm infants, pregnant women, and elderly individuals as well as those patients affected by chronic and immune compromising medical conditions. In addition, these groups are undervaccinated for a number of reasons, including lack of awareness of vaccine-preventable diseases and uncertainty or misconceptions about the safety and efficacy of vaccination by parents and healthcare providers. The presence of these nonresponders/undervaccinated individuals represents a major health and economic burden to society, which will become particularly difficult to address in settings with limited public resources. This review describes innovative and experimental approaches that can help identify specific genomic profiles defining nonresponder individuals for whom specific interventions might be needed. We will provide examples that show how such information can be useful to identify novel biomarkers of safety and immunogenicity for future vaccine trials. Finally, we will discuss how system biology “OMICs” data can be used to design bioinformatic tools to predict the vaccination outcome providing genetic and molecular “signatures” of protective immune response. This strategy may soon enable identification of signatures highly predictive of vaccine safety, immunogenicity, and efficacy/protection thereby informing personalized vaccine interventions in vulnerable populations.
PB Hindawi
SN 2314-8861
YR 2019
FD 2019
LK http://hdl.handle.net/10347/21194
UL http://hdl.handle.net/10347/21194
LA eng
NO otugno, N., Ruggiero, A., Santilli, V., Manno, E., Rocca, S., Zicari, S., Amodio, D., Colucci, M., Rossi, P., Levy, O., Martinon-Torres, F., Pollard, A. and Palma, P., 2019. OMIC Technologies and Vaccine Development: From the Identification of Vulnerable Individuals to the Formulation of Invulnerable Vaccines. Journal of Immunology Research, 2019, pp.1-10.
NO This work was supported by Associazione Volontari Bambino Gesù and Ricerca Corrente Ospedale Pediatrico Bambino Gesù 2017/2018. The Precision Vaccines Program is supported in part by NIH/NIAID Human Immunology Project Consortium U19 AI118608 and an internal award from the Boston Children’s Hospital Department of Pediatrics
DS Minerva
RD 24 abr 2026